Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Available Tools to Facilitate Early Patient Access to Medicines in the EU and the USA: Analysis of Conditional Approvals and the Implications for Personalized Medicine.

Leyens L, Richer É, Melien Ø, Ballensiefen W, Brand A.

Public Health Genomics. 2015;18(5):249-59. doi: 10.1159/000437137. Epub 2015 Aug 28.

2.

An index of barriers for the implementation of personalised medicine and pharmacogenomics in Europe.

Horgan D, Jansen M, Leyens L, Lal JA, Sudbrak R, Hackenitz E, Bußhoff U, Ballensiefen W, Brand A.

Public Health Genomics. 2014;17(5-6):287-98. doi: 10.1159/000368034. Epub 2014 Nov 15.

PMID:
25401385
3.

The simian immunodeficiency virus envelope glycoprotein contains multiple signals that regulate its cell surface expression and endocytosis.

Bowers K, Pelchen-Matthews A, Höning S, Vance PJ, Creary L, Haggarty BS, Romano J, Ballensiefen W, Hoxie JA, Marsh M.

Traffic. 2000 Aug;1(8):661-74.

4.

Recycling of the yeast v-SNARE Sec22p involves COPI-proteins and the ER transmembrane proteins Ufe1p and Sec20p.

Ballensiefen W, Ossipov D, Schmitt HD.

J Cell Sci. 1998 Jun;111 ( Pt 11):1507-20.

5.
6.

Sec12p requires Rer1p for sorting to coatomer (COPI)-coated vesicles and retrieval to the ER.

Boehm J, Letourneur F, Ballensiefen W, Ossipov D, Démollière C, Schmitt HD.

J Cell Sci. 1997 Apr;110 ( Pt 8):991-1003.

Supplemental Content

Loading ...
Support Center